Bellevue, WA, United States of America

Sagar Rane

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Sagar Rane in Abuse-Deterrent Dosage Forms

Introduction

Sagar Rane is an accomplished inventor based in Bellevue, WA (US). He has made significant contributions to the field of pharmaceuticals, particularly in developing innovative dosage forms that address the critical issue of drug abuse.

Latest Patents

Sagar Rane holds two patents, with his latest focusing on abuse-deterrent dosage forms containing esketamine. These immediate release oral dosage forms are designed with features that deter abuse and resist misuse. The formulations provide protection against overdose, whether from accidental or intentional ingestion of multiple doses. They also exhibit abuse-resistant properties when physically manipulated or administered in a manner inconsistent with oral dosing. This innovation aims to ensure safer use of esketamine, particularly in preventing higher than therapeutic doses.

Career Highlights

Rane's work at Clexio Biosciences Ltd. has positioned him as a key player in the pharmaceutical industry. His expertise in creating formulations that prioritize patient safety and efficacy has garnered attention and respect among his peers.

Collaborations

Sagar Rane collaborates with notable colleagues, including Derek V Moe and Randal A Seburg. Their combined efforts contribute to advancing research and development in the field of abuse-deterrent medications.

Conclusion

Sagar Rane's innovative work in developing abuse-deterrent dosage forms represents a significant advancement in pharmaceutical safety. His contributions are vital in addressing the challenges of drug abuse and ensuring patient well-being.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…